Transcription profiling of human lung cancer cells treated with dasatinib, imatinib, nilotinib or PD0325901

ABSTRACT: Cell Line: This experiment was designed to measure the transcriptional responses to four kinase inhibitors across a five-logarithm dose range. The A549 human lung cancer cell line was treated with dasatinib, imatinib or nilotinib (4 hours and 20 hours) or PD0325901 (4 hours). Treatments used a 12-point dose range (30 uM with 3-fold dilutions down to 0.17 nM; 0.5% DMSO vehicle for all treatments). Experimental design prevented row or column handling effects being confounded with dose effect.

ORGANISM(S): Homo sapiens

SUBMITTER: Jian Cao 

PROVIDER: E-TABM-585 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress